Who makes Part B - mutiple rising dose 1?

Part B - mutiple rising dose 1 is developed by Brilliant Inspiration Biotherapeutics.

What development phase is Part B - mutiple rising dose 1 in?

Part B - mutiple rising dose 1 is in Phase 1.

Last reviewed 2026-04-19 · How we verify

Part B - mutiple rising dose 1

Brilliant Inspiration Biotherapeutics · Phase 1 active Small molecule

At a glance

Generic name	Part B - mutiple rising dose 1
Also known as	Mutiple dose 1, Mutiple dose 2
Sponsor	Brilliant Inspiration Biotherapeutics
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled XQ-001 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Part B - mutiple rising dose 1 CI brief — competitive landscape report
Part B - mutiple rising dose 1 updates RSS · CI watch RSS
Brilliant Inspiration Biotherapeutics portfolio CI